Evidence map›Paper›PMID 35107736›Full record

ArticleMolecular biology reports2022

Accelerated embryonic stem cell screening with a highly efficient genotyping pipeline.

Roger Caothien, Charles Yu, Lucinda Tam, Robert Newman, Brian Nakao, Tuija Alcantar, Natasha Bacarro, Juan Reyes, Anna Pham, Merone Roose-Girma

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Advanced Technologies and Automation in mES Cell Workflow.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Roger CaothienDepartment of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6286-7767
Charles YuDepartment of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA.
Lucinda TamDepartment of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3101-6684
Robert NewmanDepartment of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA.
Brian NakaoDepartment of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA.
Tuija AlcantarDepartment of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA.
Natasha BacarroDepartment of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA.
Juan ReyesDepartment of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA.
Anna PhamDepartment of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA.
Merone Roose-GirmaDepartment of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA. girma.meron@gene.com.ORCID http://orcid.org/0000-0003-1601-571X
Genmab (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGene targeting in mouse ES cells replaces or modifies genes of interest; conditional alleles, reporter knock-ins, and amino acid changes are common examples of how gene targeting is used. For example, enhanced green fluorescent protein or Cre recombinase is placed under the control of endogenous genes to define promoter expression patterns. METHODS AND

resultsThe most important step in the process is to demonstrate that a gene targeting vector is correctly integrated in the genome at the desired chromosomal location. The rapid identification of correctly targeted ES cell clones is facilitated by proper targeting vector construction, rapid screening procedures, and advances in cell culture. Here, we optimized and functionally linked magnetic activated cell sorting (MACS) technology as well as multiplex droplet digital PCR (ddPCR) to our ES cell screening process to achieve a greater than 60% assurance that ES clones are correctly targeted. In a further refinement of the process, drug selection cassettes are removed from ES cells with adenovirus technology. We describe this improved workflow and illustrate the reduction in time between therapeutic target identification and experimental validation.

conclusionIn sum, we describe a novel and effective implementation of ddPCR, multiMACS, and adenovirus recombinase into a streamlined screening workflow that significantly reduces timelines for gene targeting in mouse ES cells.

Indexed as

Embryonic Stem CellsGenetic VectorsAllelesAnimalsGene TargetingGenotypeMiceES cellsGene targetingGenotypingMagnetic activated cell sorting MACSMultiplex digital PCR ddPRCTransgenic mice

Identifiers

PMID35107736
OpenAlexW4210693923

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.